CTOs on the Move


 
Sema4 is a rapidly growing patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.sema4.com
  • 333 Ludlow Street North Tower, 8th floor
    Stamford, CT USA 06902
  • Phone: 800.298.6470

Executives

Name Title Contact Details

Funding

Sema4 raised $121M on 07/29/2020
Sema4 raised $200M on 01/18/2022

Similar Companies

Cybrexa

Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company`s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology.

Genocea

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.

Avalon Pharmaceuticals

Avalon Pharmaceuticals , Inc. is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MGI PHARMA

MGI PHARMA, Inc. is a Lake Villa, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Akero Therapeutics

Akero Therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.